The outlook revision is based on a number of financial and strategic challenges, including an operating loss related to Geisinger’s health plan’s exchange product.
Moody’s Investors Service also affirmed the “Aa2” and “Aa2/VMIG 1” ratings on Geisinger’s outstanding bonds. The rating affirmations are based on Geisinger’s large size, leading market position and exceptional clinical reputation.
More articles on healthcare finance:
Surprise billing legislation stalls again on East Coast
For-profit hospital stock report: Week of Nov. 21-25
Medicare cancer patients without additional coverage hit with high out-of-pocket costs: 4 things to know
